We use cookies to improve your experience. By continuing to browse this site, you accept our cookie policy.×
Skip main navigation
Open Drawer MenuClose Drawer Menu
Aging Health
Bioelectronics in Medicine
Biomarkers in Medicine
Breast Cancer Management
CNS Oncology
Colorectal Cancer
Concussion
Epigenomics
Future Cardiology
Future Medicine AI
Future Microbiology
Future Neurology
Future Oncology
Future Rare Diseases
Future Virology
Hepatic Oncology
HIV Therapy
Immunotherapy
International Journal of Endocrine Oncology
International Journal of Hematologic Oncology
Journal of 3D Printing in Medicine
Lung Cancer Management
Melanoma Management
Nanomedicine
Neurodegenerative Disease Management
Pain Management
Pediatric Health
Personalized Medicine
Pharmacogenomics
Regenerative Medicine
Commentary

Overcoming chemoresistance in cancer stem cells with the help of microRNAs in colorectal cancer

    Andrew Fesler

    Department of Pathology, Stony Brook University, School of Medicine, Stony Brook, New York, 11794 NY, USA

    Search for more papers by this author

    ,
    Shixiang Guo

    Department of Pathology, Stony Brook University, School of Medicine, Stony Brook, New York, 11794 NY, USA

    Search for more papers by this author

    ,
    Hua Liu

    Department of Pathology, Stony Brook University, School of Medicine, Stony Brook, New York, 11794 NY, USA

    Search for more papers by this author

    ,
    Ning Wu

    Department of Pathology, Stony Brook University, School of Medicine, Stony Brook, New York, 11794 NY, USA

    Search for more papers by this author

    &
    Jingfang Ju

    *Author for correspondence:

    E-mail Address: jingfang.ju@stonybrookmedicine.edu

    Department of Pathology, Stony Brook University, School of Medicine, Stony Brook, New York, 11794 NY, USA

    Search for more papers by this author

    Published Online:18 May 2017https://doi.org/10.2217/epi-2017-0041

    Abstract

    It has been recognized that acute resistance to chemotherapy mediated by post-transcriptional and translational control is crucial to influence response and survival in cancer treatment. Tumor cells are highly heterogeneous and have the ability to adapt a resistance phenotype through epigenetic regulations such as microRNAs. This poses a major challenge to the treatment of advanced stage colon cancer patients. Colon cancer stem cells have been identified as one of the major contributors to resistance of colon cancer to chemotherapy. Through various mechanisms, these cells are able to resist the effects of traditional chemotherapeutics. The challenge posed by these cells is further enhanced by their plastic nature, where cells can transition between non-stem cancer cells and cancer stem cells creating a moving target. In this editorial, we discuss some of the recent advancements in overcoming chemoresistance associated with colon cancer stem cells with the help of microRNAs.

    References

    • 1 American Cancer Society. Cancer Facts & Figures 2013. www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2013/cancer-facts-and-figures-2013.pdf.
      Google Scholar
    • 2 Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 61(5), 759–767 (1990).
      Medline CASGoogle Scholar
    • 3 Fearon ER. Molecular genetics of colorectal cancer. Annu. Rev. Pathol. 6, 479–507 (2011).
      Medline CASGoogle Scholar
    • 4 O'brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumor growth in immunodeficient mice. Nature 445(7123), 106–110 (2007).
      MedlineGoogle Scholar
    • 5 Ricci-Vitiani L, Lombardi DG, Pilozzi E et al. Identification and expansion of human colon-cancer-initiating cells. Nature 445(7123), 111–115 (2007).
      Medline CASGoogle Scholar
    • 6 Hongo K, Tanaka J, Tsuno NH et al. CD133(-) cells, derived from a single human colon cancer cell line, are more resistant to 5-fluorouracil (FU) than CD133(+) cells, dependent on the beta1-integrin signaling. J. Surg. Res. 175(2), 278–288 (2012).
      Medline CASGoogle Scholar
    • 7 Taniguchi H, Moriya C, Igarashi H et al. Cancer stem cells in human gastrointestinal cancer. Cancer Sci. 107(11), 1556–1562 (2016).
      Medline CASGoogle Scholar
    • 8 Todaro M, Alea MP, Di Stefano AB et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 1(4), 389–402 (2007).
      Medline CASGoogle Scholar
    • 9 Lee MR, Ji SY, Mia-Jan K, Cho MY. Chemoresistance of CD133(+) colon cancer may be related with increased survivin expression. Biochem. Biophys. Res. Commun. 463(3), 229–234 (2015).
      Medline CASGoogle Scholar
    • 10 Wu S, Wang X, Chen J, Chen Y. Autophagy of cancer stem cells is involved with chemoresistance of colon cancer cells. Biochem. Biophys. Res. Commun. 434(4), 898–903 (2013).
      Medline CASGoogle Scholar
    • 11 Kobayashi S, Yamada-Okabe H, Suzuki M et al. LGR5-positive colon cancer stem cells interconvert with drug-resistant LGR5-negative cells and are capable of tumor reconstitution. Stem Cells 30(12), 2631–2644 (2012).
      Medline CASGoogle Scholar
    • 12 Touil Y, Igoudjil W, Corvaisier M et al. Colon cancer cells escape 5FU chemotherapy-induced cell death by entering stemness and quiescence associated with the c-Yes/YAP axis. Clin. Cancer. Res. 20(4), 837–846 (2014).
      Medline CASGoogle Scholar
    • 13 Lotti F, Jarrar AM, Pai RK et al. Chemotherapy activates cancer-associated fibroblasts to maintain colorectal cancer-initiating cells by IL-17A. J. Exp. Med. 210(13), 2851–2872 (2013).
      Medline CASGoogle Scholar
    • 14 Vermeulen L, De Sousa EMF, Van Der Heijden M et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat. Cell Biol. 12(5), 468–476 (2010).
      Medline CASGoogle Scholar
    • 15 Croce CM, Calin GA. miRNAs, cancer, and stem cell division. Cell 122(1), 6–7 (2005).
      Medline CASGoogle Scholar
    • 16 Fang Y, Xiang J, Chen Z et al. miRNA expression profile of colon cancer stem cells compared with non-stem cells using the SW1116 cell line. Oncol. Rep. 28(6), 2115–2124 (2012).
      Medline CASGoogle Scholar
    • 17 Fesler A, Zhang N, Ju J. The expanding regulatory universe of p53 in gastrointestinal cancer. F1000Research 5, 756 (2016).
      MedlineGoogle Scholar
    • 18 Song B, Wang Y, Kudo K, Gavin EJ, Xi Y, Ju J. miR-192 Regulates dihydrofolate reductase and cellular proliferation through the p53-microRNA circuit. Clin. Cancer Res. 14(24), 8080–8086 (2008).
      Medline CASGoogle Scholar
    • 19 Xi Y, Shalgi R, Fodstad O, Pilpel Y, Ju J. Differentially regulated micro-RNAs and actively translated messenger RNA transcripts by tumor suppressor p53 in colon cancer. Clin. Cancer Res. 12(7 Pt 1), 2014–2024 (2006).
      Medline CASGoogle Scholar
    • 20 Bu P, Chen KY, Chen JH et al. A microRNA miR-34a-regulated bimodal switch targets Notch in colon cancer stem cells. Cell Stem Cell 12(5), 602–615 (2013).
      Medline CASGoogle Scholar
    • 21 Bu P, Wang L, Chen KY et al. A miR-34a-numb feedforward loop triggered by inflammation regulates asymmetric stem cell division in intestine and colon cancer. Cell Stem Cell 18(2), 189–202 (2016).
      Medline CASGoogle Scholar
    • 22 Wang L, Bu P, Ai Y et al. A long non-coding RNA targets microRNA miR-34a to regulate colon cancer stem cell asymmetric division. eLife 5, pii: e14620 (2016).
      Google Scholar
    • 23 Hwang WL, Jiang JK, Yang SH et al. microRNA-146a directs the symmetric division of snail-dominant colorectal cancer stem cells. Nat. Cell Biol. 16(3), 268–280 (2014).
      Medline CASGoogle Scholar
    • 24 Yu Y, Nangia-Makker P, Farhana L, G Rajendra S, Levi E, Majumdar AP. miR-21 and miR-145 cooperation in regulation of colon cancer stem cells. Mol. Cancer 14, 98 (2015).
      MedlineGoogle Scholar
    • 25 Iliou MS, Da Silva-Diz V, Carmona FJ et al. Impaired DICER1 function promotes stemness and metastasis in colon cancer. Oncogene 33(30), 4003–4015 (2014).
      Medline CASGoogle Scholar
    • 26 Le Rolle AF, Chiu TK, Zeng Z et al. Oncogenic KRAS activates an embryonic stem cell-like program in human colon cancer initiation. Oncotarget 7(3), 2159–2174 (2016).
      MedlineGoogle Scholar
    • 27 Jin Y, Jiang Z, Guan X et al. miR-450b-5p suppresses stemness and the development of chemoresistance by targeting SOX2 in colorectal cancer. DNA Cell Biol. 35(5), 249–256 (2016).
      Medline CASGoogle Scholar
    • 28 Sakaguchi M, Hisamori S, Oshima N, Sato F, Shimono Y, Sakai Y. miR-137 regulates the tumorigenicity of colon cancer stem cells through the Inhibition of DCLK1. Mol. Cancer Res. 14(4), 354–362 (2016).
      Medline CASGoogle Scholar
    • 29 Jones MF, Hara T, Francis P et al. The CDX1-microRNA-215 axis regulates colorectal cancer stem cell differentiation. Proc. Natl Acad. Sci. USA 112(13), E1550–E1558 (2015).
      Medline CASGoogle Scholar
    • 30 Zhai H, Fesler A, Ba Y, Wu S, Ju J. Inhibition of colorectal cancer stem cell survival and invasive potential by hsa-miR-140–5p mediated suppression of Smad2 and autophagy. Oncotarget 6(23), 19735–19746 (2015).
      MedlineGoogle Scholar
    • 31 Zhai H, Song B, Xu X, Zhu W, Ju J. Inhibition of autophagy and tumor growth in colon cancer by miR-502. Oncogene 32(12), 1570–1579 (2012).
      MedlineGoogle Scholar
    • 32 Karaayvaz M, Zhai H, Ju J. miR-129 promotes apoptosis and enhances chemosensitivity to 5-fluorouracil in colorectal cancer. Cell Death Dis. 4, e659 (2013).
      Medline CASGoogle Scholar
    • 33 Fesler A, Zhai H, Ju J. miR-129 as a novel therapeutic target and biomarker in gastrointestinal cancer. Onco Targets Ther. 7, 1481–1485 (2014).
      MedlineGoogle Scholar